Neurodegenerative Diseases, published by KARGER, is a prominent academic journal dedicated to advancing the field of neurology and neuroscience. With an ISSN of 1660-2854 and E-ISSN 1660-2862, this journal serves as a vital platform for researchers, professionals, and students engaged in the exploration of neurodegenerative disorders from various perspectives, including clinical applications and therapeutic interventions. Spanning two decades since its inception in 2004 and set to converge in 2024, it has steadily built a reputation within the academic community, achieving a commendable Q2 ranking in clinical neurology and Q3 in general neurology according to the 2023 category quartiles. The journal boasts an impressive Scopus rank of 114/400 (71st percentile) in clinical neurology and 58/192 (70th percentile) in neuroscience neurology. While not classified as open access, the publication provides critical insights into the latest research and developments, making it an essential resource for anyone dedicated to understanding and combating neurodegenerative diseases.

ANNALS OF THE RHEUMATIC DISEASES, published by BMJ Publishing Group, stands as a leading academic journal in the realm of rheumatology and related fields, including biochemistry, immunology, and genetics. With an esteemed impact factor and a consistent ranking in the upper echelons of its category (Q1) as per the latest evaluations, this journal represents the forefront of research and innovation, fostering scientific advancement from 1945 to the present. As the top journal in the Medicine - Rheumatology category and achieving remarkable percentiles in various interdisciplinary categories, it serves as a critical platform for researchers, clinicians, and students dedicated to understanding and addressing rheumatic diseases. Although it does not currently offer open access, its rigorous peer-review process ensures the dissemination of high-quality research findings that are paramount in enhancing clinical practices and advancing scientific discourse. Readers can expect to be challenged and inspired by the breadth of studies and reviews that address the complexities of rheumatology and its intersecting scientific domains.

Epilepsia Open is a premier open access journal dedicated to advancing the field of neurology, particularly in the area of epilepsy research and clinical practice. Published by WILEY since 2016, this journal aims to provide a platform for high-quality, peer-reviewed research that fosters collaboration among researchers, clinicians, and educators within the global neurological community. With an impactful presence in the field, it holds a prestigious Q2 ranking in both Neurology and Clinical Neurology categories as of 2023 and has been recognized for its contributions to the understanding of epilepsy through its diverse range of articles, reviews, and clinical studies. Researchers and practitioners can benefit from the journal's open access model, which ensures that valuable findings are readily available to the public, promoting further developments in treatment and care. The journal's significant visibility is reflected in its Scopus rankings, where it ranks in the top half of peer-reviewed journals in both Neurology and Neuroscience categories. For those committed to improving the lives of those affected by epilepsy, Epilepsia Open represents a crucial resource for cutting-edge knowledge and innovative practices.

REVUE NEUROLOGIQUE, published by MASSON EDITEUR, is a prestigious academic journal that plays an essential role in the field of neurology. With a rich history spanning from 1946 to the present, this journal focuses on both foundational and clinical aspects of neurology, underscoring its significance within the medical community. Holding an impressive Q2 ranking in both general and clinical neurology categories as of 2023, REVUE NEUROLOGIQUE is recognized for its contribution to advancing neurological science, as evidenced by its Scopus rankings, with a notable position in the 62nd percentile for clinical neurology. The journal fosters an environment for rigorous research and is instrumental for professionals and scholars aiming to stay abreast of the latest developments in neurological disorders and treatments. Although it is not an open-access publication, it offers a wealth of vital research through its issues, appealing to those engaged in both clinical practice and academic research in neurology.

NEUROPSYCHOPHARMACOLOGY is a prestigious academic journal dedicated to advancing our understanding of the intricate relationship between psychiatric disorders and pharmacological treatments. Published by SpringerNature in the United Kingdom, this leading journal has been a cornerstone in the field since its inception in 1987, with a converged publication timeline extending to 2024. With a remarkable impact factor and illustrious rankings—being positioned 19th in Psychiatry and Mental Health and 16th in Pharmacology—NEUROPSYCHOPHARMACOLOGY is recognized for its rigorous peer-reviewed research that informs clinical practice and enhances therapeutic interventions. The journal is classified in Q1 quartile categories for both Pharmacology and Psychiatry and Mental Health, highlighting its commitment to excellence. Researchers, professionals, and students are encouraged to contribute to this vital dialogue, as the journal does not currently offer open access, emphasizing the importance of curated, high-quality content. By publishing innovative studies and reviews, NEUROPSYCHOPHARMACOLOGY plays a crucial role in shaping the future of mental health treatments and understanding neurobiological mechanisms, making it an indispensable resource for those at the forefront of psychiatric research.

ACTA NEUROLOGICA SCANDINAVICA is a prestigious journal published by Wiley that has significantly contributed to the field of neurology and neuroscience since its inception in 1961. With a broad scope encompassing clinical and experimental research, this journal is esteemed for its rigorous peer-review process and high-quality publications. Located in the United Kingdom, it is recognized in the 2023 category quartiles as Q1 in Medicine (miscellaneous) and Q2 in both Neurology and Clinical Neurology, indicating its strong influence and relevance within the medical community. With an H-index demonstrating consistent citation impact, ACTA NEUROLOGICA SCANDINAVICA holds a Scopus rank of #86 out of 400 in Clinical Neurology, reflecting its contribution to advancing current knowledge and practice. Researchers, professionals, and students alike will find in this journal a valuable resource for the latest findings, discussions, and developments in understanding neurological disorders and treatments, furthering educational and clinical endeavors alike.

Acta Epileptologica is a prominent open-access journal published by SPRINGERNATURE, dedicated to advancing research in the fields of neurology and clinical neurology. With its ISSN 2096-9384 and E-ISSN 2524-4434, this journal has established itself as a key resource for researchers and practitioners worldwide, particularly since its transition to open access in 2019. Based in the United Kingdom, Acta Epileptologica aims to disseminate high-quality research and foster scholarly collaboration, as evidenced by its consistent Q3 ranking in both neurology and clinical neurology categories as of 2023. Although currently positioned in the lower percentiles on Scopus, the journal plays a critical role in exploring emerging trends and novel therapeutic approaches in epilepsy research, making it an essential platform for academics, healthcare professionals, and students deeply invested in the evolving landscape of neurological disorders.

NEUROLOGY, published by Lippincott Williams & Wilkins, stands as a premier journal in the field of neurology, holding an esteemed Q1 category ranking in clinical neurology as of 2023. Established in 1951, this journal has been a critical resource for the dissemination of cutting-edge research and clinical advancements, with an impressive Scopus rank of 24 out of 400, placing it in the 94th percentile among its peers. NEUROLOGY serves as a vital platform for neurologists, researchers, and medical professionals seeking to stay abreast of the latest findings and innovations in the treatment and understanding of neurological disorders. With its rigorous peer-review process and commitment to excellence, NEUROLOGY remains essential reading for all individuals dedicated to advancing the science and practice of neurology, contributing significantly to the ongoing dialogue in this vital area of medicine.

European Journal of Paediatric Neurology, published by Elsevier Science Ltd, is a premier academic journal dedicated to advancing the field of paediatric neurology. With its ISSN 1090-3798 and E-ISSN 1532-2130, this journal serves as a vital resource for researchers, clinicians, and students alike, focusing on the latest findings and innovative treatments in paediatric neurological disorders. The journal has established itself as a leading publication in its field, achieving a Q1 classification in Pediatrics, Perinatology and Child Health, and holding a reputable Q2 status in Clinical Neurology as of 2023. Positioned within the top 88th percentile in Pediatrics and the 76th percentile in Clinical Neurology according to Scopus ranks, it publishes rigorous peer-reviewed articles that contribute significantly to clinical practice and research. Although not open access, the journal provides vital insights into the complexities of neurological conditions affecting the pediatric population, making it an essential tool for scholars and professionals striving to improve child health outcomes. With a publication trajectory spanning from 1997 to 2024, it continues to be at the forefront of paediatric neurological research, inspiring innovation and collaboration in the scientific community.

Schizophrenia Research is a premier academic journal focused on innovative research within the domain of psychiatry and mental health, published by Elsevier. With its ISSN 0920-9964 and E-ISSN 1573-2509, the journal has established a strong presence since its inception in 1988, evolving to publish cutting-edge findings up to 2024. Positioned in Q1 in Psychiatry and Mental Health and Q2 in Biological Psychiatry, it ranks impressively in the 83rd percentile among its peers, according to Scopus, ranking #93/567 in the field of Medicine, and #12/51 in Neuroscience. This journal serves as a vital platform for the dissemination of significant scientific advancements and theoretical insights into schizophrenia, fostering a deeper understanding of mental illnesses. Although it operates on a subscription basis, its critical role in informing both ongoing research and clinical practices cannot be overstated, making it an essential resource for researchers, clinicians, and students alike. Join a global community dedicated to improving mental health outcomes and advancing the study of schizophrenia through this reputable publication.